CD39 and PD-L1 co-expression may serve as potential indicators for evaluating the efficacy of neoadjuvant immunotherapy in esophageal squamous cell carcinoma
{{output}}
Esophageal squamous cell carcinoma (ESCC) contributes a major therapeutic challenge in gastrointestinal oncology due to its aggressive behavior. Neoadjuvant immunotherapy combined with chemotherapy (NIT) has emerged as a novel treatment strategy for ESCC. Howe... ...
